- Report
- February 2024
- 70 Pages
Iran
From €4312EUR$4,750USD£3,714GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2532EUR$2,789USD£2,181GBP
- Report
- June 2025
- 400 Pages
Global
From €4492EUR$4,949USD£3,870GBP
- Report
- May 2026
- 200 Pages
Canada
From €2532EUR$2,789USD£2,181GBP
- Report
- August 2024
- 150 Pages
Global
From €2532EUR$2,789USD£2,181GBP
- Report
- May 2023
- 147 Pages
Global
From €4492EUR$4,949USD£3,870GBP
- Report
- March 2026
- 136 Pages
France
From €3630EUR$3,999USD£3,127GBP
- Report
- May 2024
- 140 Pages
Global
From €3630EUR$3,999USD£3,127GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4312EUR$4,750USD£3,714GBP
- Report
- February 2024
- 80 Pages
Europe
From €4312EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
Germany
From €4312EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
Italy
From €4312EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
Oman
From €4312EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
Egypt
From €4312EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4312EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
France
From €4312EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
Saudi Arabia
From €4312EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4312EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4312EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4312EUR$4,750USD£3,714GBP

Sulfonylureas are a class of drugs used to treat type 2 diabetes. They work by stimulating the pancreas to produce more insulin, which helps the body to better process glucose. They are usually taken orally, and are often used in combination with other diabetes medications. Sulfonylureas are generally well-tolerated, but can cause side effects such as hypoglycemia, weight gain, and gastrointestinal upset.
The sulfonylureas market is a subset of the larger diabetes drugs market. It is a competitive market, with a range of products available from different manufacturers. The market is expected to grow in the coming years, driven by increasing prevalence of diabetes and the development of new drugs.
Some of the major companies in the sulfonylureas market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more